NO20070750L - Nye sykliske aminobenzosyrederivater - Google Patents

Nye sykliske aminobenzosyrederivater

Info

Publication number
NO20070750L
NO20070750L NO20070750A NO20070750A NO20070750L NO 20070750 L NO20070750 L NO 20070750L NO 20070750 A NO20070750 A NO 20070750A NO 20070750 A NO20070750 A NO 20070750A NO 20070750 L NO20070750 L NO 20070750L
Authority
NO
Norway
Prior art keywords
atom
benzoic acid
acid derivatives
cyclic amino
amino benzoic
Prior art date
Application number
NO20070750A
Other languages
English (en)
Norwegian (no)
Inventor
Yasuo Takano
Koji Murakami
Masahiro Nomura
Kazuhiro Yumoto
Takehiro Shinozaki
Shigeki Isogai
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of NO20070750L publication Critical patent/NO20070750L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20070750A 2004-08-11 2007-02-08 Nye sykliske aminobenzosyrederivater NO20070750L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004234603 2004-08-11
PCT/JP2005/014718 WO2006016637A1 (ja) 2004-08-11 2005-08-11 新規環状アミノ安息香酸誘導体

Publications (1)

Publication Number Publication Date
NO20070750L true NO20070750L (no) 2007-03-08

Family

ID=35839397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070750A NO20070750L (no) 2004-08-11 2007-02-08 Nye sykliske aminobenzosyrederivater

Country Status (15)

Country Link
US (1) US7902367B2 (es)
EP (1) EP1780210A4 (es)
JP (1) JPWO2006016637A1 (es)
KR (1) KR20070050475A (es)
CN (1) CN101014595A (es)
AU (1) AU2005272389B2 (es)
BR (1) BRPI0515015A (es)
CA (1) CA2575039A1 (es)
IL (1) IL180314A0 (es)
MX (1) MX2007001634A (es)
NO (1) NO20070750L (es)
NZ (1) NZ552501A (es)
RU (1) RU2391340C2 (es)
WO (1) WO2006016637A1 (es)
ZA (1) ZA200700064B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862464A4 (en) * 2005-03-23 2010-08-25 Kyorin Seiyaku Kk NEW CYCLIC AMINOPHENYL ALKANIC ACID DERIVATIVE
FR2934265B1 (fr) * 2008-07-23 2010-07-30 Sanofi Aventis Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique
FR2938537B1 (fr) * 2008-11-14 2012-10-26 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
JP2012051803A (ja) * 2008-12-25 2012-03-15 Kyorin Pharmaceutical Co Ltd 環状アミノ安息香酸エステル誘導体の製造方法
US20110118314A1 (en) * 2009-11-16 2011-05-19 Weiya Yun Piperidine analogs as glycogen synthase activators
CN102532123B (zh) * 2010-12-29 2016-03-09 中国医学科学院药物研究所 噻唑-5-甲酰胺化合物、及其制法和药物组合物与用途
CA2842364A1 (en) * 2011-07-29 2013-02-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
MX349712B (es) 2011-07-29 2017-08-09 Karyopharm Therapeutics Inc Moduladores del transporte nuclear que contienen hidrazida y sus usos.
DK3404027T3 (da) 2012-05-09 2020-06-02 Biogen Ma Inc Cellekernetransportmodulatorer og anvendelser deraf
US10202366B2 (en) 2013-03-15 2019-02-12 Karyopharm Therapeutics Inc. Methods of promoting wound healing using CRM1 inhibitors
EP3492455B1 (en) 2013-06-21 2023-05-17 Karyopharm Therapeutics Inc. 1,2,4-triazoles as nuclear transport modulators and use in the treatment of specific forms of cancer
CN103382198B (zh) * 2013-07-16 2014-11-19 浙江医药高等专科学校 吡唑酰胺类化合物、其制备方法和用途
MX2017002013A (es) 2014-08-15 2017-05-12 Karyopharm Therapeutics Inc Polimorfos de selinexor.
TWI642671B (zh) * 2015-10-28 2018-12-01 台灣神隆股份有限公司 依魯替尼之製備方法及其中間體
EP3397633A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
WO2021055936A1 (en) * 2019-09-20 2021-03-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small-molecule inhibitors for the β-catenin/b-cell lymphoma 9 protein−protein interaction
WO2024022521A1 (zh) * 2022-07-28 2024-02-01 南通环聚泰生物科技有限公司 靶向BCL9/β-连环蛋白互相作用的小分子化合物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2419970C3 (de) 1974-04-25 1980-06-12 Hoechst Ag, 6000 Frankfurt 3-<l-Pyrrolidinyl)-4-phenoxy-5sulfamoylbenzoesäure und Verfahren zu ihrer Herstellung
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
GB1485607A (en) 1975-06-06 1977-09-14 Nippon Shinyaku Co Ltd Morpholinone derivatives and their production
DE2624569A1 (de) 1975-06-17 1977-01-13 Nippon Shinyaku Co Ltd Neue carbonsaeurederivate und verfahren zu ihrer herstellung
JPS5283676A (en) 1976-01-01 1977-07-12 Nippon Shinyaku Co Ltd Novel morpholinone derivative
JPS6391354A (ja) 1986-10-02 1988-04-22 Yamanouchi Pharmaceut Co Ltd 新規なカルボン酸誘導体
JP2949454B2 (ja) 1992-01-28 1999-09-13 武田薬品工業株式会社 安定なビタミン製剤
US5227490A (en) 1992-02-21 1993-07-13 Merck & Co., Inc. Fibrinogen receptor antagonists
JPH0672861A (ja) 1992-07-09 1994-03-15 Takeda Chem Ind Ltd 着色固形製剤
ES2156120T3 (es) 1992-12-08 2001-06-16 Ss Pharmaceutical Co Derivados arilamidicos.
DE4404183A1 (de) 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
ATE277004T1 (de) 1994-12-19 2004-10-15 Nippon Soda Co Benzamidoximderivate, verfahren zu ihrer herstellung und ein bakterizid für landwirtschaft und gartenbau
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CN1233241A (zh) 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
US20020032330A1 (en) 1996-12-24 2002-03-14 Yutaka Nomura Propionic acid derivatives
US6376503B1 (en) 1997-06-18 2002-04-23 Merck & Co., Inc Alpha 1a adrenergic receptor antagonists
SK15072000A3 (sk) 1998-04-10 2001-08-06 Japan Tobacco Inc. Amidové zlúčeniny
US6291459B1 (en) 1998-08-12 2001-09-18 Smithkline Beecham Corporation Calcilytic compounds
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
SK15522001A3 (sk) 1999-04-28 2002-06-04 Aventis Pharma Deutschland Gmbh Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú
ES2287016T3 (es) 1999-04-28 2007-12-16 Sanofi-Aventis Deutschland Gmbh Derivados de diaril-acido como ligandos del receptor ppar.
US6673817B1 (en) 1999-05-24 2004-01-06 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
CA2382573C (en) 1999-08-23 2007-05-22 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
CN1186315C (zh) 1999-09-17 2005-01-26 杏林制药株式会社 o－茴香酰胺衍生物
TWI262185B (en) 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
WO2001027082A1 (fr) 1999-10-08 2001-04-19 Meiji Seika Kaisha, Ltd. DERIVES DE 3-AMINOPIPERIDINE UTILISES COMME ANTAGONISTES DE L'INTEGRINE αvβ3
US20050059669A1 (en) 1999-10-08 2005-03-17 Keiichi Ajito M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity
WO2001027090A1 (en) 1999-10-08 2001-04-19 Meiji Seika Kaisha, Ltd. m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRINαvβ3 ANTAGONISM
PE20011010A1 (es) 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
US20030040531A1 (en) 2000-01-25 2003-02-27 Kazuyuki Fujishima Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
WO2002037937A2 (en) 2000-11-07 2002-05-16 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
WO2002044130A1 (fr) 2000-11-29 2002-06-06 Kyorin Pharmaceutical Co., Ltd. Dérivés d'acide carboxylique substitués
JPWO2002044127A1 (ja) 2000-11-29 2004-04-02 杏林製薬株式会社 置換カルボン酸誘導体
CA2430846A1 (en) 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Substituted carboxylic acid derivatives
AU2002222573A1 (en) 2000-12-05 2002-06-18 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002064549A1 (en) 2001-02-15 2002-08-22 Pfizer Products Inc. Ppar agonists
US6548538B2 (en) 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
JPWO2002098840A1 (ja) * 2001-06-04 2004-09-16 エーザイ株式会社 カルボン酸誘導体及びその塩もしくはそのエステルからなる医薬
UA76773C2 (uk) 2001-08-31 2006-09-15 Санофі-Авентіс Дойчланд Гмбх Діарилциклоалкільні похідні, спосіб їх одержання і їх застосування як ppar-активаторів
GB0123765D0 (en) 2001-10-03 2001-11-21 Bayer Ag Para-amino benzoic acids
IL160970A0 (en) 2001-11-06 2004-08-31 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
EP1447401A1 (en) 2001-11-22 2004-08-18 Ono Pharmaceutical Co., Ltd. Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
CN1312121C (zh) 2001-12-11 2007-04-25 杏林制药株式会社 取代苯基丙酸衍生物的新的稳定结晶及其制造方法
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
US6908939B2 (en) 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
FR2833949B1 (fr) * 2001-12-21 2005-08-05 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS PPARy, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
EA007270B1 (ru) 2002-03-13 2006-08-25 Янссен Фармацевтика Н.В. Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
PL213783B1 (pl) 2002-03-13 2013-05-31 Janssen Pharmaceutica Nv Podstawiona pochodna piperydyny lub piperazyny, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
US7361783B2 (en) 2002-05-27 2008-04-22 Kyorin Pharmaceutical Co., Ltd. (2S)-2-ethylphenylpropionic acid derivative
EP1525185A1 (en) 2002-07-24 2005-04-27 PTC Therapeutics, Inc. Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease
JP4475406B2 (ja) 2002-07-30 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション 異常脂血症および他の脂質障害の治療用のＰＰＡＲα選択的化合物
DE60332738D1 (de) 2002-07-30 2010-07-08 Merck Sharp & Dohme Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
US6768353B2 (en) * 2002-07-31 2004-07-27 Freescale Semiconductor, Inc. Prescaler method and apparatus
PL378268A1 (pl) 2002-11-26 2006-03-20 Pfizer Products Inc. Aktywatory PPAR
DE10308352A1 (de) 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308354A1 (de) 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200500362A (en) * 2003-04-09 2005-01-01 Japan Tobacco Inc 5-membered heteroaromatic ring compound and pharmaceutical use thereof
KR20060007385A (ko) 2003-04-16 2006-01-24 교린 세이야꾸 가부시키 가이샤 경구 고형 제제
JPWO2005009942A1 (ja) 2003-07-28 2006-09-07 杏林製薬株式会社 光学活性置換フェニルプロピオン酸誘導体
WO2005115975A1 (ja) 2004-05-28 2005-12-08 Tanabe Seiyaku Co., Ltd. アリールアルキルアミン化合物及びその製法
EP1862464A4 (en) 2005-03-23 2010-08-25 Kyorin Seiyaku Kk NEW CYCLIC AMINOPHENYL ALKANIC ACID DERIVATIVE

Also Published As

Publication number Publication date
MX2007001634A (es) 2007-04-23
ZA200700064B (en) 2007-12-27
CN101014595A (zh) 2007-08-08
CA2575039A1 (en) 2006-02-16
AU2005272389A1 (en) 2006-02-16
EP1780210A1 (en) 2007-05-02
NZ552501A (en) 2010-03-26
KR20070050475A (ko) 2007-05-15
WO2006016637A1 (ja) 2006-02-16
AU2005272389B2 (en) 2011-08-04
US7902367B2 (en) 2011-03-08
RU2007108415A (ru) 2008-09-20
IL180314A0 (en) 2007-06-03
JPWO2006016637A1 (ja) 2008-05-01
EP1780210A4 (en) 2009-06-10
US20070249580A1 (en) 2007-10-25
RU2391340C2 (ru) 2010-06-10
BRPI0515015A (pt) 2008-07-01

Similar Documents

Publication Publication Date Title
NO20070750L (no) Nye sykliske aminobenzosyrederivater
NO20085169L (no) Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes
MY142807A (en) Benzimidazole derivative and use thereof.
AU2016333963C1 (en) PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
NO944704L (no) Tiazolidinderivater og farmasöytiske blandinger som inneholder disse
TW200700069A (en) Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
NO20093275L (no) 1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase
NO20091560L (no) Biaryleterureaforbindelser
US20100069433A1 (en) Prophylactic and/or therapeutic agent for hyperlipidemia
CA2592345A1 (en) Piperidine and azetidine derivatives as glyt1 inhibitors
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
EP3442948A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
NO20082747L (no) Arylisoksazol-4-yl-imidazolderivater
BRPI0507248A (pt) compostos do tipo hidrazina e sua utilização em composições farmacêuticas para o tratamento de doença cardiovasculares
RU2015147509A (ru) Новые композиции для предупреждения и/или лечения дегенеративных расстройств центральной нервной системы
RU2010148387A (ru) Производное фенилпропионовой кислоты и его применение
RU2010107603A (ru) Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний
ZA200805740B (en) Novel polyunsaturated compounds, method for preparing same and compositions containing same
NO20061281L (no) Fenyleddiksyrederivat, fremgangmate for fremstilling av det samme, og anvendelse
CY1109678T1 (el) Νεα παραγωγα 3-φαινυλπροπιονικου οξεος και χρηση αυτων ως συνδετηρες του υποδοχεα ppar-γαμμα
TW200616679A (en) Modified-release preparation
RU2007127724A (ru) Новые производные 3-фенилпропиновой кислоты для лечения диабета
NO20061152L (no) Ny fremgangsmate for syntese av N-(S)-1-karboksybuty)-(S)-alanin og anvendelse derav for a syntetisere perindopril
WO2023086854A1 (en) Treatment of myotonic disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application